Whoever Japan Big Pharma forgets will be happy

Japan has an Arzneimittel problem. When a new and innovative Arzneimittel has a new kind of investment point of view, the country has fallen behind competitors in the US, Europe and China, that is a pharmaceutical power center that has been developed.

A long-standing policy of trust in the reward of high costs has involved the foreign pharmaceutical industry being excluded from the market in the Mediterranean country that is being marketed.

The “Attractiveness of Domestic Pharmaceutical Markets for Domestic and Foreign Pharmaceutical Companies,” wrote Hideki Sato, Media Director at Chugai Pharmaceutical, on Anfrage.

Chugai, a Japanese company and repairer, of the Swiss Roche control, war in the years of the drittgrösste Verkäufer of verschreibungspflichtigen Medikamenten in Japan.

Vas Narasimhan, CEO of Novartis in Switzerland, told Japan’s Nachrichtenagentur Nikkei in JanuaryExternal linkthe Arzneimittelverluste (NichtVerfügbarkeit von Arzneimitteln, weil sie nicht auf den Markt kommen oder zurückbewegingen) en Arzneimittelverzögerungen (Verzögerungen bei der Verfügbarkeit von Arzneimitteln) zu serious Problemen in Land seien.

Regie launched Reforms

I have followed the Japanese direction for a year on a well of the reforms, an ausländische Arzneimittelhersteller has started. This is for the background of the Befürchtung, the patient: I do not want to go to the new Arzneimitteln anymore and the country in the Arzneimittelforschung back to fall.

The strategy played a major role on July 30, when Prime Minister Fumio Kishida outlined a roadmapExternal linkum Japan has a “Land der Arzneimittelentdeckung” for machines and the supply with the new Arzneimitteln solutions. Concrete is one of the “weighty masses” of the direction.

“Some Japanese patients don’t have another Wahl, either as part of the import of medicine or if they want to make the Australian trip to Australia,” Kishida, 30, said in July at the Gate Opening Summit on Innovative Drug Discovery in Tokyo.

It is a trade with a meeting, one of the Regierungsbeamt:innen, Expert:innen and Abgesandte grovere Pharmaunternehmen, darunter auch von Novartis, teilnahmen.

“Wir wollen nicht, dass die Patients sich so fühlen, and wir wollen auch ein Ort sein, wo die Arzneimittelforschung nicht nur den Patients in Japan, sonondern in der gezen Welt hilft.”

After the Japanese Ministry of Health left the American medicine in Japan on March 143, 2023 in Europe or the US, there was still no green light.

Those medical drugs have not been a problem for 86 years, a Zulassung in Japan is a trifle.

The new roadmap sees massively, Japan is an attractive country for pharmaceutical companies. So it is that in the coming years the Clinical Study has never started with starting medicines and until 2028 more as Start-ups in the Medikamentenentwicklung have started, which have had a large financial foundation.

The massive crackdowns and further reforms, which are in Kraft in April, will be a pre-Isaufschlag External linkof 5-10% of new drug treatment.

“It is a fact that it is positive about the pharmaceutical industry,” says Sato von Chugai Pharmaceutical. The further reforms are followed by the analysis of the relief of the clinical trial of phase 1 in Japan.

Rising Costs in Health Care

The world of fierce criticism in the Japanese pharmaceutical sector lies in the overarching health care systems, which began in 2011. Damals change the alternative country governments and the high price of a resulting enterprise and burden the direction, after the costs of such costs.

Years of war in Japan, destroyed by U.S. forces, the largest pharmaceutical market in the United States.

While the Japanese Arzneimittelbehörde of the Arzneimittelherstellern demands the duration of Phase 1 clinical studies in Japan, one of its consequences, lohnte sich das Geschäft, those high price powers that costs wader lawt.

A study External linkSince the British Office of Health Economics since 1982, the Arbitration Price in Japan (for a comparable product) was 17% higher than in Switzerland and West Germany, over 40% higher than in the United Kingdom and over 60%. higher than in France or Italian. The land war started with the Zulassung and the battle against the costs of Arzneimitteln.

Greater investment in Research and Development in Japan has yielded a new drug. About 16% of the new drugs that were introduced internationally between 1980 and 1984 originated in Japan, while an estimated 15% came from Germany and 13% from Switzerland.

Foreign medicine manufacturers such as active following Japanese innovations from companies such as Takeda, Esai and Chugai.

But the alternative Bevölkerung Japans setzte the national Krankenversicherungssystem zunehmend under Druck.

After the Weltbank believed that prosperity in countries would reach 7% of GDP in the year 2000, it would quickly increase to 11% in 2020.

This is the end External linkZwar der Entwicklung other OECD-Länder, although in Japan a significantly larger Anteil der Ausgaben (84%) öffentlich financing as in OECD-Durchschnitt (65%).

I started the Directing, the Restoration of Preissenkungen in Singing. See it 2015 for more information about 50 changes in the price for medical care, see belowExternal link a Vertreter der Pharmaindustrie 2022 gegenüber Reuters.

Andrew Chen, a consultant who lived in Japan for a year and went to Hong Kong to see the Health Advances Company, said that in Japan, the Arzneimittelpreise would often run into problems and what could happen in the US.

The Regie has not yet started with the prize for Arzneimittel, but there are severe criticisms of the innovative Arzneimittel festivities, which have resulted in a beschlenigte Zulassung.

Sinking novelties

These mass products come from the American pharmaceutical industry, which has a new drug treatment and has dampened the Research Seed.

In 2023, 20 years ago, a “new” company was launched in Japan, the last month of 2014 and less than half, would appear on the market in the United States as often.

“We are careful to bring new products to the market in Japan. In the war in Japan, there was a market for market forces, while the Unternehmen, especially für Medikamente gegen seltene Krankheiten, others Marken de Vorzug geben,” said Chen.

From 1995 to 2018, the Japanese market and the development of the world’s pharmaceutical industry have sunk from 18.5% to 5.5%, with a release date of 2022. Paper External linkthe Centre for Life Sciences Innovation was reorganised. The centre is part of the Information Technology and Innovation Foundation, a US-based think tank for science and technology policy.

The paper is rolled up on the back of the paper in the pre-arranged manner, but the possibilities are achieved.

It is clear that Japanese biopharmaceutical legislation has become one of the longest-running regulatory systems and reforms in the world through continued state investments in scientific research, Swiss industry and the university.

In the transition period when China created a new and new market and developed an even more important Innovation Center, it was no longer the case that more legislation was developed.

More

More

Whoever gets the US sanctions against China is financed by the Swiss Pharma Industry

Dieser Inhalt is veröffentlicht

June 15, 2024

The American plans, the companies of Big Pharma and Biotech companies in China are at work. It is a bet with Schweizer Branchengrössen.

More about US sanctions against China by Schweizer Pharmaindustrie

The Japanese Anteil studies and the first clinical studies went from 11% in the year 2013 to 4% in the year 2023 in back. I look at the figures of the Anteil Chinas from 3% to 28%, with an IQVIA policyExternal link reformed. China has Japan from Japan as zweitgrössten Pharmamarkt überholt.

The road to innovation

“The main group, where the development in Japan is stagnating, is that the Japanese market is not attractive,” said one of the Japanese pharmaceutical companies, who would never be able to generate SWI swissinfo.ch again. “Profit-hungry companies are thus losing their way, in Japan new medicines to develop.”

The development of technology for small biotech companies or start-ups, which are at the forefront of medical technology and the US, would have become a major burden in the United States.

A pharmaceutical manufacturer knows that reforms in the country are continuing.

“Japan is one of our four priority regions, in the context of innovative trading options,” explains a speaker from Novartis on request.

“Japan is a much larger and more attractive market with a high level of expertise and a workforce of billions, where all the interests of the company are so strongly supported,” says Ryo Hanamura, partner at the business consulting firm Arthur Little in Japan.

Editiert von Nerys Avery/vm/ts, from the English version by Marc Leutenegger

Read more

Further

Back

More

Was this the last medicine of the world?

Dieser Inhalt is veröffentlicht

April 23, 2024

Zolgensma of the Swiss Manufacturer Novartis can earn a price of 2.1 million dollars on the market for a year. Has Daraus become?

More Was it good medicine for the world?

More

Was it a fairer price for a medicine?

Dieser Inhalt is veröffentlicht

April 23, 2024

The path to a fair price is more transparent, says legal and medical expert Kerstin Noëlle Vokinger.

More Was it a fairer price for a medicine?